SetPoint Medical

04/14/2026

We’re joining Arthritis Foundation this spring to celebrate 25 years of Walk to Cure Arthritis events!

Rheumatoid arthritis awareness is a cause very near and dear to our hearts, and there's no better way to celebrate this milestone than by showing up, lacing up, and walking alongside some amazing people fighting for better treatments for patients across the nation.

Come find at one of the cities below and join the movement 👟

03/20/2026

Wondering about other people's experience using the to treat their RA? Chicago's WGN TV just profiled a local patient who has had the device implanted for over 2 years. Hear what she has to say, as well as insights from her surgeon and rheumatologist.

Learn more and request a therapy consultation at setpointmedical.com/patients.

Individual outcomes vary. Safety info: spm.care/ISI

https://wgntv.com/news/medical-watch/new-implantable-device-offers-relief-for-rheumatoid-arthritis-patients/

The device is covered by Medicare but not by all commercial insurance, particularly Blue Cross Blue Shield.

12/29/2025

2025 was a momentous year for our team, our clinician partners, and the warriors who championed the development of . This year marked a series of milestones that will shape the future of RA care for years to come. Here’s to continuing this momentum and increasing access to a brand-new RA treatment modality in the New Year!

For full safety information, please visit spm.care/ISI

11/26/2025

This Thanksgiving, we are reflecting on the people who make our work possible. Every advancement in how we treat autoimmune conditions depends upon close collaboration with the impacted communities and immense dedication from advocates and medical professionals whose work drives the field forward.

We are grateful for the many individuals living with RA who share their stories with us, for the families and caregivers closely involved in the RA fight, and for the rheumatologists, surgeons, nurses, and clinic teams who bring skill, compassion, and cutting-edge science to the care they provide.

From all of us at SetPoint Medical, and to the SetPoint Medical team as well, we want to say thank you.

08/21/2025

The New York Times characterizes the SetPoint System as offering "new hope to patients incapacitated by rheumatoid arthritis, a chronic condition that afflicts 1.5 million Americans and is often resistant to treatment."

We're so pleased to see this coverage of the FDA approval of the SetPoint System in the New York Times! Read the full feature story to learn more about the life-changing power of neuroimmune modulation:

Individual outcomes vary. Please see important safety information at spm.care/ISI

The device stimulates the vagus nerve, signaling the body to tamp down the inflammation that contributes to the disease.

02/22/2021

SetPoint Medical is seeking highly-motivated and talented individuals to join the company! Multiple opportunity’s available to join this one of a kind team!

Click here to apply:

03/01/2019

SetPoint Medical is seeking an experienced, high caliber quality inspector to inspect incoming materials, in-process production, and finished products to assure quality design and manufacturing of medical devices and components.

03/01/2019

SetPoint's looking for Quality, Quality people! Know anyone! Have them apply below!!!!

05/24/2018

It's Arthritis Awareness Month. We are doing all we can to fight this debilitating disease.

04/23/2018

We are looking for great people to join a great team. Accounting Clerk - AP, apply at: https://goo.gl/gWNb5W

03/26/2018

We are recruiting!!!
Find info at: https://clinicaltrials.gov/ct2/show/NCT03437473

01/16/2018

SetPoint Medical reported positive 24-month results using bioelectronic vagus stimulation to treat sick rheumatoid arthritis patients in a European trial led by Professor Paul-Peter Tak. All 17 study subjects stayed on therapy past 24-months with several patients achieving and maintain DAS remission. SetPoint's bioelectronic therapy for RA appears to deliver safe, tolerable and efficacious results. The results were presented last week at the NANS meeting in Las Vegas.